اشترك بالحزمة الذهبية واحصل على وصول غير محدود شمرا أكاديميا
تسجيل مستخدم جديد$^7$Be and $^{22}$Na radionuclides for a new therapy of cancer
50
0
0.0
(
0
)
اسأل ChatGPT حول البحث
ﻻ يوجد ملخص باللغة العربية
The $^{10}$B isotope has been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy, which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use either a lower nuclide concentration in the target tissues, or a lower neutron irradiation flux. By detecting the characteristic $gamma$ radiation from the spontaneous decay of the radionuclides, one can image and control their accumulation. These advantages could be critical for the revival of the NCT as a safer, more efficient and more widely used cancer therapy.
قيم البحث
اقرأ أيضاً
We study the spatial distributions of $beta^+$-activity produced by therapeutic beams of $^3$He and $^{12}$C ions in various tissue-like materials. The calculations were performed within a Monte Carlo model for Heavy-Ion Therapy (MCHIT) based on the
GEANT4 toolkit. The contributions from $^{10,11}$C, $^{13}$N, $^{14,15}$O, $^{17,18}$F and $^{30}$P positron-emitting nuclei were calculated and compared with experimental data obtained during and after irradiation. Positron emitting nuclei are created by $^{12}$C beam in fragmentation reactions of projectile and target nuclei. This leads to a $beta^+$-activity profile characterised by a noticeable peak located close to the Bragg peak in the corresponding depth-dose distribution. On the contrary, as the most of positron-emitting nuclei are produced by $^3$He beam in target fragmentation reactions, the calculated total $beta^+$-activity during or soon after the irradiation period is evenly distributed within the projectile range. However, we predict also the presence of $^{13}$N, $^{14}$O, $^{17,18}$F created in charge-transfer reactions by low-energy $^3$He ions close to the end of their range in several tissue-like media. The time evolution of $beta^+$-activity profiles was investigated for both kinds of beams. Due to the production of $^{18}$F nuclide the $beta^+$-activity profile measured 2 or 3 hours after irradiation with $^{3}$He ions will have a distinct peak correlated with the maximum of depth-dose distribution. We found certain advantages of low-energy $^{3}$He beams over low-energy proton beams for reliable PET monitoring during particle therapy of shallow located tumours. In this case the distal edge of $beta^+$-activity distribution from $^{17}$F nuclei clearly marks the range of $^{3}$He in tissues.
Cold atmospheric plasma (CAP) was shown to affect cells not only directly, but also indirectly by means of plasma pre-treated solution. This study investigated a new application of CAP generated in deionized (DI) water for the cancer therapy. In our
experiments, the CAP solution was generated in DI water using helium as carrier gas. We report on the effects of this plasma solution in breast (MDA-MD-231) and gastric (NCI-N87) cancer cells. The results revealed that apoptosis efficiency was dependent on the plasma exposure time and on the levels of reactive oxygen and nitrogen species (ROS and RNS). The plasma solution that resulted from 30-minute treatment of DI water had the most significant effect in the rate of apoptosis.
Charged Particle Therapy is a technique for cancer treatment that exploits hadron beams, mostly protons and carbons. A critical issue is the monitoring of the dose released by the beam to the tumor and to the surrounding tissues. We present the desig
n of a new tracking device for monitoring on-line the dose in ion therapy through the detection of secondary charged particles produced by the beam interactions in the patient tissues. In fact, the charged particle emission shape can be correlated with the spatial dose release and the Bragg peak position. The detector uses the information provided by 12 layers of scintillating fibers followed by a plastic scintillator and a small calorimeter made of a pixelated Lutetium Fine Silicate crystal. Simulations have been performed to evaluate the achievable spatial resolution and a possible application of the device for the monitoring of the dose profile in a real treatment is presented.
Fast procedures for the beam quality assessment and for the monitoring of beam energy modulations during the irradiation are among the most urgent improvements in particle therapy. Indeed, the online measurement of the particle beam energy could allo
w assessing the range of penetration during treatments, encouraging the development of new dose delivery techniques for moving targets. Towards this end, the proof of concept of a new device, able to measure in a few seconds the energy of clinical proton beams (from 60 to 230 MeV) from the Time of Flight (ToF) of protons, is presented. The prototype consists of two Ultra Fast Silicon Detector (UFSD) pads, featuring an active thickness of 80 um and a sensitive area of 3 x 3 mm2, aligned along the beam direction in a telescope configuration, connected to a broadband amplifier and readout by a digitizer. Measurements were performed at the Centro Nazionale di Adroterapia Oncologica (CNAO, Pavia, Italy), at five different clinical beam energies and four distances between the sensors (from 7 to 97 cm) for each energy. In order to derive the beam energy from the measured average ToF, several systematic effects were considered, Monte Carlo simulations were developed to validate the method and a global fit approach was adopted to calibrate the system. The results were benchmarked against the energy values obtained from the water equivalent depths provided by CNAO. Deviations of few hundreds of keV have been achieved for all considered proton beam energies for both 67 and 97 cm distances between the sensors and few seconds of irradiation were necessary to collect the required statistics. These preliminary results indicate that a telescope of UFSDs could achieve in a few seconds the accuracy required for the clinical application and therefore encourage further investigations towards the improvement and the optimization of the present prototype.
This paper reports on the conclusions of a 2013 Joint DOE/NCI Workshop, and translates clinical accelerator facility requirements into accelerator and beam-delivery technical specifications. Available or feasible accelerator technologies are compared
, including a new concept for a compact, CW, and variable energy light ion accelerator currently under development. This new light ion accelerator is based on advances in non-scaling Fixed-Field Alternating gradient (FFAG) accelerator design. The new design concepts combine isochronous orbits with long (up to 4m) straight sections in a compact racetrack format allowing inner circulating orbits to be energy selected for low-loss, CW extraction, effectively eliminating the high-loss energy degrader in conventional CW cyclotron designs.
سجل دخول لتتمكن من نشر تعليقات
التعليقات
جاري جلب التعليقات
سجل دخول لتتمكن من متابعة معايير البحث التي قمت باختيارها
